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A B S T R A C T   
Rheumatoid arthritis is a chronic autoimmune disease characterised by joint synovial inflammation, along with 
cartilage and bone tissue destruction. Dendrimers can offer new opportunities as drug delivery systems of 
molecules of interest. Herein we aimed to develop poly(amidoamine) dendrimers (PAMAM), functionalised with 
chondroitin sulphate (CS), lined with anti-TNF α antibodies (Abs) to provide anti-inflammatory properties. 
Physicochemical characterisation demonstrated that anti-TNFα Abs-CS/PAMAM dendrimer NPs were success-
fully produced. The in vitro studies revealed that CS/PAMAM dendrimer NPs did not affect the ATDC5 and THP-1 
cell lines’ metabolic activity and proliferation, presenting good cytocompatibility and hemocompatibility. 
Moreover, anti-TNFα Abs-CS/PAMAM dendrimer NPs showed suitable TNF α capture capacity, making them 
appealing for new immunotherapies in RA patients.   
1. Introduction 
Modern lifestyle has been accompanied by an increased incidence of 
age-related and autoimmune diseases. Autoimmune disorders have 
several aetiologies, from genetic susceptibility or immune dysregulation 
to environmental factors [1,2]. 
Rheumatoid arthritis (RA) is a systemic autoimmune disorder with 
undisclosed cause, characterised by polyarthritis and joint synovial 
inflammation, as well as cartilage and bone tissue destruction [3]. 
Currently, RA treatment strategies include disease-modifying anti- 
rheumatic drugs (DMARDs), typically supported by non-steroidal anti- 
inflammatory drugs (NSAIDs) and/or corticosteroids to reduce the pain 
and inflammation [4]. However, many side effects are associated with 
these treatments, limiting their therapeutic efficacy. Therefore, it is 
essential to develop and validate new drug delivery strategies for RA 
treatment that specifically target inflamed joints and attenuate the 
damage to healthy tissues [5]. 
High levels of the pro-inflammatory Tumour Necrosis Factor alfa 
(TNF α) are observed in the synovial fluid and the synovium of patients 
with RA, making this cytokine an appealing target for treatment [6]. 
Furthermore, this pro-inflammatory cytokine induces the production of 
other pro-inflammatory cytokines such as Interleukin (IL)-1, IL-6, IL-8, 
and Matrix metalloproteinases (MMPs) which also play a very important 
role in the pathology of rheumatoid arthritis [7,8]. Targeting TNF α with 
anti-TNF α agents, such as antibodies (Abs) and fusion proteins, has 
shown to induce long-term improvements in RA manifestations and 
signs [9]. For this reason, several smart nanocarriers for delivering drugs 
have been developed and tested for RA treatment [10,11]. 
Dendrimers offer new opportunities as drug delivery systems with 
improved effectiveness and specificity. These dendrimers NPs allow a 
time-controlled delivery, of single or multiple compounds, reducing the 
uptake of toxic agents and side effects of certain drugs, while improving 
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and prolonging its bioavailability [12,13]. In particular poly(amido-
amine) (PAMAM) dendrimers, polymeric structures sphere-shaped with 
branches, have been studied as nanocarriers for targeted drug delivery. 
The functional groups on the surface allow their modification to con-
jugate small molecules and Abs [14]. The potential of PAMAM den-
drimers in the treatment of RA has been increasingly explored, and 
literature demonstrated that these nanoparticles allow a controlled 
release of molecules of interest and have anti-inflammatory properties 
[15,16]. Moreover, the combination of dendrimers with synthetic and 
natural biodegradable polymers could benefit a closer interaction with 
living cells, enhancing its biological performance [17]. Chondroitin 
sulphate (CS) is one of the main components of the extracellular matrix 
(ECM) and is abundant in several living tissues, such as cartilage. This 
sulphated glycosaminoglycan shows numerous appealing characteristics 
like antioxidant, antiatherosclerotic, antithrombosis, anticoagulant and 
non-immunogenic properties, and as a natural polymer, it is also 
biocompatible and biodegradable [18–20]. Moreover, considering this 
delivery system is intended to be administrated in the intra-articular 
space, and CS is one of the main components of the cartilage tissue, 
the functionalisation of the PAMAM dendrimers with this natural 
polymer may increase its affinity with the tissue of interest (cartilage). 
Herein it was hypothesised that PAMAM dendrimers functionalised 
with CS and linked to specific Abs could have advantageous properties 
for the treatment of RA. Thus, this work consists of the development and 
evaluation of an innovative approach for RA treatment, based on tar-
geted delivery, using an anti-TNF α Abs linked to PAMAM dendrimers. 
The PAMAM were functionalised with CS and synthesised as nano-
carriers, to help receptor-ligand interaction and low toxicity, while the 
covalently linked anti-TNF α Abs provides anti-inflammatory properties. 
The successful functionalisation of PAMAM dendrimer NPs was 
confirmed through their physicochemical characterisation, using 
energy-dispersive X-ray spectroscopy, proton nuclear magnetic reso-
nance spectroscopy, Fourier transform infrared spectroscopy, Scanning 
Transmission Electron Microscope, Dynamic light scattering, electro-
phoretic light scattering, and Rheometer methodologies. In vitro studies 
were performed to analyse the effect of the PAMAM dendrimer NPs on 
the viability and proliferation of human chondrogenic, lymphocytic, and 
monocytic cells. The dendrimers’ internalisation, NPs-induced haemol-
ysis, interaction with plasma proteins, and anti-inflammatory activity 
were also evaluated. 
2. Materials and methods 
2.1. Synthesis of the CS/PAMAM dendrimer NPs 
Chondroitin sulphate A sodium salt from bovine trachea (463.363 g/ 
mol) and PAMAM carboxylic-terminated dendrimers (generation 1.5, 
20% methanolic solution), with an ethylenediamine core, were pur-
chased from Sigma-Aldrich (USA). CS/PAMAM dendrimer NPs were 
prepared as referred by Shaunak et al., 2004, with some modifications. 
Briefly, 20 g/mol of (2-N-Morpholino)ethanesulfonic acid hydrate 
(MES) (Sigma-Aldrich) was added to 50 g L− 1 of PAMAM (diluted in 
MES), then N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydro-
chloride (EDC) (Sigma-Aldrich, USA) (4 equivalents) and sulfo-NHS N- 
Hydroxysulfosuccinimide sodium salt ≥98% (HPLC) (Sigma-Aldrich, 
USA) (2 equivalents), also in MES, were mixed and stirred for 15 min, 
with the first solution of PAMAM. Then, chondroitin sulphate (20 
equivalents) was added with EDC (4 equivalents) and the reactions were 
mixed and stirred for 15 min. The PAMAM mixture was added to the CS 
mixture and stirred for 24 h. The solution was dialysed against distilled 
water using a Dialysis Tubing membrane, benzoylated (Laborspirit, 
Loures), for 48 h. CS/PAMAM dendrimer NPs were obtained by freezing 
the solution at − 80 ◦C and freeze-drying (Telstar-LyoAlfa 10/15) for 
approximately 7 days. 
2.2. Labelling of CS/PAMAM dendrimer NPs with fluorescein 
isothiocyanate (FITC) 
The CS/PAMAM dendrimer NPs were linked to Fluorescein isothio-
cyanate (FITC) (Sigma-Aldrich, USA). Firstly, 10 mg mL− 1 of CS/ 
PAMAM solution was prepared in a carbonate-bicarbonate coupled 
buffer (pH 9.2). Then 50 μL of the FITC (10 mg mL− 1)/DMSO (anhy-
drous dimethyl sulfoxide) solution was added per each mL of CS/ 
PAMAM dendrimer NPs solution under agitation and kept in the dark at 
4 ◦C for 8 h. Lastly, the FITC-labelled CS/PAMAM dendrimer NPs were 
dialysed in ultrapure water for 48 h. The product was achieved after 
dialysis and freeze-drying. 
2.3. Physiochemical characterisation 
2.3.1. Proton nuclear magnetic resonance spectroscopy (1H NMR) 
CS/PAMAM dendrimer NPs was solubilised in deuterium water oxide 
(1 mg mL− 1) at room temperature and the sample was transferred to 
NMR tube. The NMR spectra were obtained on a Bruker AVANCE 400 
spectrometer, at 50 ◦C using a resonance frequency of 400 MHz. To 
process and analyse the obtained spectra, MestReNova 9.0 Software was 
used. 
2.3.2. Fourier transform infrared spectroscopy (FTIR) 
The CS/PAMAM dendrimer NPs were mixed with potassium bromide 
and moulded into a transparent pellet using a press. Transmission 
spectra were acquired on an IR Prestige-21 spectrometer (Shimadzu, 
Japan), using wavenumber range between 4400 and 400 cm− 1, 32 scans 
and a resolution of 4 cm− 1. 
2.3.3. Energy-dispersive X-ray spectroscopy (EDS) 
CS/PAMAM dendrimer NPs samples were coated with carbon (Fisons 
Instruments, Polaron SC 508, UK). The electric current was set at 18 mA 
with a coating time of 120 s. The sulphur, calcium, sodium, carbon and 
oxygen elemental analysis were achieved through an X-ray detector 
(Pentafet model 5526, UK) attached to the S-360 microscope, and a 
voltage of 10 kV was used. 
2.3.4. Dynamic light scattering (DLS) and electrophoretic light scattering 
(ELS) 
Particle size and zeta potential of CS/PAMAM dendrimer NPs were 
measured in a particle analyser (Zetasizer Nano ZS, Malvern In-
struments, UK). Particle size analysis was made by DLS technique, in an 
ultrapure water solution with 1 mg mL− 1 of CS/PAMAM dendrimer NPs. 
Zeta potential of nanoparticles was evaluated by ELS, at pH 7.4 phos-
phate buffer saline (PBS) solution. 
2.3.5. Atomic force microscopy (AFM) 
The morphology of the nanoparticles was evaluated through AFM. 
The CS/PAMAM dendrimer NPs were dissolved in ultrapure water to 
achieve a final concentration of 1 mg mL− 1 and transferred to the surface 
of a 9.9 mm mica disc (Agar Scientific, England). The samples were 
evaluated using the Tapping model TM with a MultiMode AFM con-
nected to a NanoScope III controller (Veeco, USA) with noncontact sil-
icon nanoprobes (ca. 300 kHz) from Nanosensors, Switzerland. Images 
were plane-fitted using the third-degree-flatten procedure included in 
NanoScope software version 1.5. The particle morphology and size were 
both analysed with NanoScope 1.5 software. 
2.3.6. Scanning Transmission Electron Microscope (STEM) 
The size and morphology of CS/PAMAM dendrimer NPs were also 
obtained by STEM. The nanoparticles were diluted in ultrapure water to 
a final concentration of 0.1 mg mL− 1 and then 2 μL were placed on 
copper grids at 37 ◦C overnight for observation. 
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2.3.7. Rheometer methodologies 
Rheological analyses were performed using Kinexus pro+rheometer 
with the acquisition software rSpace (Malvern). The rotational experi-
ments were performed using a cone-plate measuring system composed 
by an upper stainless-steel cone of 40 mm of diameter and a cone angle 
of 4◦. Shear viscosity was obtained as a function of the shear rate, from 
0.001 to 0.1 s− 1 at 37 ◦C. The oscillatory experiments were made to 
obtain frequency sweep curves, after LVER determination. 
3. TNF-α Abs linked to CS/PAMAM dendrimer nanoparticles 
3.1. Functionalisation 
The CS/PAMAM dendrimer NPs linked to rabbit polyclonal anti- 
TNF-α antibodies (ab7742, Abcam, United Kingdom) was obtained 
through a crosslinking reaction. A 0.2 g L− 1 solution of CS/PAMAM in 5 
mL MES was mixed with EDC (4 equivalents) and NHS (2 equivalents) 
for 15 min. Next, 20 equivalents of anti-TNF α Abs were added with EDC 
(4 equivalents) and were stirred for 15 min. Then, CS/PAMAM den-
drimer NPs mixture was added to anti-TNF α Abs mixture and stirred for 
24 h. The solution was dialysed against distilled water for 48 h. Anti-TNF 
α Abs-CS/PAMAM dendrimer NPs were obtained through dialysis and 
freeze-drying. 
3.2. Physicochemical characterisation 
The immobilisation of the Abs by CS/PAMAM was evaluated by 
fluorescence spectrometer FP-8500 (Jasco). Briefly, anti-TNF α Abs-CS/ 
PAMAM dendrimer NPs and CS/PAMAM dendrimer NPs were mixed 
with a secondary antibody anti-rabbit IgG-labelled with Alexa Fluor 488 
dye (Molecular probes, USA), in PBS solution (1:1000) for 1 h to detect 
the conjugation of anti-TNF α Abs to CS/PAMAM dendrimer NPs. The 
solutions were centrifuged, and the supernatants were visualised in the 
spectrometer. 
The determination of the degree of TNF α captured by anti-TNF α 
Abs-CS/PAMAM dendrimer NPs was analysed by the incubation of the 
dendrimers with 1000 pg mL− 1 of TNF α (Peprotech, United Kingdom) 
for 6 h at room temperature. After centrifugation, the supernatants were 
kept at − 80 ◦C for further analysis. Then, the free TNF-α concentration 
in the samples after incubation was measured using a Human TNF-alpha 
DuoSET ELISA kit (R&D systems, USA) and a DuoSet Ancillary Reagent 
Kit 2 (R&D systems, USA). The calibration curve was prepared using 
TNF-α standard solutions, with concentrations from 0 to 1000 pg mL− 1, 
which were also included in the ELISA plate. The samples were 
measured in the microplate reader (Synergy HT, BIO-TEK) with an op-
tical density of 450 nm. 
4. In vitro studies 
4.1. Cell cultures 
Chondrogenic ATDC 5 cell line (European Collection of Authenti-
cated Cell Culture, England), human monocytic cell line (THP-1) and 
differentiated human T lymphocyte cell line (Jurkat) were used to 
analyse the effects of CS/PAMAM dendrimer NPs in cartilage and im-
mune system cells. 
ATDC 5 cell line was expanded in DMEM medium (Dulbecco’s 
Modified Eagle Medium: Nutrient Mixture F-12, Alfagene, Portugal). 
THP-1 and Jurkat cell lines were expanded in RPMI medium (RPMI 1640 
Medium, GlutaMAX™ Supplement, HEPES, Gibco, Life Technologies, 
Grand Island, NY), supplemented with 10% Heat Inactivated Foetal 
Bovine Serum, 2 mM glutamine and 100 U mL− 1 of penicillin/strepto-
mycin (PAA; Pasching, Austria), under standard culture conditions 
(37 ◦C in a humidified atmosphere, containing 5 v/v CO2). 
The experiments with the THP-1 and Jurkat cells were carried out in 
the Immunology laboratory at the University of Vigo and for that reason, 
some experimental conditions differ from the ATDC 5 cell line. When the 
conditions or the equipment used were different, it was specifically 
mentioned. 
4.2. MTS assay 
Cell viability was evaluated by MTS [3-(4,5-dimethylthiazol-2-yl)-5- 
(3-carboxymethoxyphenyl)-2(4-sulfophenyl)-2H-tetrazolium] (VWR 
International, USA). The ATDC 5 cells were seeded at a density of 1 ×
104 cells per well and incubated with different concentrations of CS/ 
PAMAM dendrimer NPs, for 72 h. Cells cultured with regular medium 
(without CS/PAMAM dendrimer NPs) were used as a control. At each 
time point, cell culture medium (DMEM-F12) was replaced by culture 
medium without phenol red, containing MTS at a 5:1 ratio, and was 
incubated for 3 h. Then, 100 μL from each well were passed into a 96- 
well plate and the absorbance was read at 490 nm. 
The Jurkat and (differentiated) THP-1 cell lines were seeded in a 96- 
well plate with a density of 3 × 104 and 1 × 104 cells per well, respec-
tively. The CS/PAMAM dendrimer NPs were administrated in serial di-
lutions 1:2 starting with the concentrations of 0.5 mg mL− 1. The cells 
were incubated with the CS/PAMAM dendrimer NPs for 48 h, in stan-
dard cell culture conditions. The remaining procedure was performed as 
previously mentioned for the ATDC 5 cell line. 
4.3. DNA quantification 
The proliferation of the ATDC5 cells upon CS/PAMAM dendrimer 
NPs administration was analysed by DNA quantification, using the 
Quanti-IT PicoGreen dsDNA Assay Kit (Alfagene, Portugal). 
ATDC5 cells were seeded at a density of 1 × 104 cells per well and 
incubated with different concentrations of CS/PAMAM dendrimer NPs 
for 72 h. Cells cultured with DMEM-F12 medium were used as control. 
After the incubation period, the cells were lysed in ultrapure water and 
stored at − 80 ◦C for further analysis. The calibration curve was per-
formed using DNA standards, prepared with concentrations ranging 
from 2 to 0 μL mL− 1. Both the calibration curve and the cells’ samples 
were quantified following the manufacturer’s instructions. The fluo-
rescence was acquired at 480/20 nm of excitation and emission of 528/ 
20 nm, in a microplate reader. The DNA concentration on the cells 
samples was determined using the standard curve. 
4.4. Flow cytometry 
For flow cytometry analysis the ATDC 5 cells were seeded at a den-
sity 4 × 105 cells per well (in a 24-well plate) and cultured with different 
concentrations of FITC-labelled CS/PAMAM NPs (0.01, 0.1 and 0.5 mg 
mL− 1), for 72 h. ATDC5 cells cultured in DMEM-F12 without CS/ 
PAMAM dendrimer NPs were used as control. The samples were 
measured using a FACSCalibur flow cytometer (BD Biosciences Immu-
nocytometry Systems, CA, USA) and the results were analysed by the 
Flowing Software 2. THP-1 cells were incubated for 3, 6 and 24 h with 
0.5 mg mL− 1 of CS/PAMAM dendrimer NPs at a cell density of 1 × 105 
cells per well, in a 24-well plate. THP-1 cells cultured with only RPMI 
medium were used as control. The samples were measured in a BD 
Accuri C6 flow cytometer (BD Biosciences, USA) and the analysis was 
performed in the cytometer software. 
4.5. Fluorescence microscopy 
For this assay the ATDC5 cells were seeded at a density of 1 × 104 
cells per well in a 24-well plate, with different concentrations of FITC- 
labelled CS/PAMAM dendrimer NPs, using the previously tested time 
points. Then, cells were fixed with 10% formalin (Sigma-Aldrich, USA) 
and stained with 4,6-diamidino-2-phenylindole, dilactate (DAPI blue, 
VWR International, USA) for nuclei and Texas Red-X phalloidin (Sigma- 
Aldrich, USA) for actin filaments of the cytoskeleton. The cells were 
I.M. Oliveira et al.                                                                                                                                                                                                                              
Materials Science & Engineering C 121 (2021) 111845
4
Fig. 1. EDS analysis (a) of CS/PAMAM dendrimer and 1H NMR in D2O at 50 ◦C (b) and FTIR (c), of PAMAM dendrimer (G = 1.5) (i), CS (ii) and the CS/PAMAM 
dendrimer NPs (iii). 
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observed under the fluorescence microscope (Axiolmager, Z1, Zeis Inc., 
Oberkochen, Germany). 
The differentiated THP-1 cells were seeded at a density of 4 × 104 
cells per well in a 24-well plate and incubated for 3 and 6 h with FITC- 
labelled CS/PAMAM dendrimer NPs. At each time point the cells were 
stained with Hoechst 33342 (1:1000) (Immnochemistry Technologies) 
and observed under a Nikon Eclipse Ti2 microscope (Nikon Instruments, 
Inc.). 
4.6. Haemolytic properties of CS/PAMAM dendrimer NPs 
Erythrocytes from whole mouse blood were used to test the hae-
molytic properties of CS/PAMAM dendrimer NPs. The blood was 
extracted into a tube with EDTA and an aliquot of 5 mL was diluted with 
PBS (1:10) in a pre-weighted tube. After centrifugation and washing 
steps, the pellet was weighed and diluted with PBS to a final concen-
tration of 3% w/v. 
The CS/PAMAM dendrimer NPs were diluted in PBS and adminis-
trated in serial dilutions 1:2 starting with the concentrations of 0.5 mg 
mL− 1. PBS and Triton x-100 were used as negative control and positive 
control, respectively. The plates were incubated for 4 h, centrifuged and 
the supernatant was collected. The samples were read at 588 nm 
absorbance using a microplate reader (Greiner Bio-one). The percentage 
of haemolysis in the samples was calculated according to the following 
Equation: 
Haemolysis (%) =
Abs (sample) − Abs (PBS)
Abs (Triton) − Abs (PBS)
× 100 
Abs: Absorbance at 558 nm 
4.7. Assessment of binding to plasma protein by fluorescence spectroscopy 
Suspensions of human albumin (HSA) and fibrinogen (Sigma- 
Aldrich, USA) at 400 μg mL− 1 and 40 μg mL− 1, respectively, were pre-
pared in PBS. Different volumes of a CS/PAMAM dendrimer NPs solu-
tion at 0.5 mg mL− 1, or PBS as the control, were sequentially added to 
the cuvette (1, 5, 10 and 20 μL). The fluorescence spectra of the plasma 
proteins were recorded after each addition using the microplate reader. 
Fibrinogen was excited at 280 nm and HSA at 290 nm and the emission 
spectra were both collected from 300 nm to 450 nm. The spectra were 
obtained using the FluorEssenceTM software. 
5. Assessment of TNF α capture by anti-TNF α Abs-CS/PAMAM 
dendrimer NPs 
The therapeutic efficacy of the NPs was evaluated in a cell inflam-
mation model, by assessing the anti-TNF α Abs-CS/PAMAM dendrimer 
NP’s ability to capture TNF α in the medium. Macrophage-differentiated 
Fig. 2. (a) AFM analysis (i) 2D, (ii) 3D (b) STEM analysis of the CS/PAMAM dendrimer NPs and (c) DLS analysis.  
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THP-1 cells were stimulated with Lipopolysaccharide (LPS) (Sigma- 
Aldrich, USA) and used as in vitro model for cell inflammation. Firstly, 
THP1 cells were seeded at a density of 1 × 106 cells/mL in RPMI with 
100 nM phorbol 12-myristate-13-acetate (PMA) (Sigma-Aldrich, USA). 
After 24 h of incubation time, the medium in the wells was replaced with 
RPMI medium without PMA and incubated for another 48 h. In order to 
induce an inflammatory response, 100 ng mL− 1 of LPS in RPMI medium 
were added to the macrophage-differentiated THP-1 cells, and the plate 
was incubated for 5 h. After LPS stimulation, 0.5 mg mL− 1 of anti-TNF α 
Abs-CS/PAMAM dendrimer NPs were added to the cells, using a medium 
with only PMA were used as control. At each time point (1 day, 3 days, 
and 7 days), the culture medium was removed from the wells, cen-
trifugated and the supernatants were stored at − 80 ◦C for further 
analysis. 
To determine the degree of TNF α captured by the anti-TNF α Abs- 
CS/PAMAM dendrimer NPs, the TNF-α concentration in the samples 
was measured using the Human TNF-alpha DuoSET ELISA kit (R&D 
systems, USA) and the DuoSet Ancillary Reagent Kit 2 (R&D systems, 
USA). The calibration curve was performed using TNF-α standard so-
lutions, with concentrations ranging from 1000 to 0 pg mL− 1, which 
were also included in the ELISA plate. The samples were analysed using 
a microplate reader, with an optical density of 450 nm (Synergy HT, 
BIO-TEK). 
6. Statistical analysis 
Statistical analysis was performed using GraphPad Prism 8 version. 
Statistical significances were determined as *p < 0.05, ** p < 0.01 and 
*** p < 0.001. All assays were performed in triplicated and results were 
presented as mean ± standard deviation. 
7. Results and discussion 
7.1. Physicochemical characterisation 
7.1.1. Chemical analysis of CS/PAMAM dendrimer NPs 
This study focused on the functionalisation of PAMAM with CS, 
conjugated to an anti-TNF α Abs. It was hypothesised that this strategy 
can be used for RA treatment, by helping receptor-ligand interaction, 
reducing toxicity, and providing anti-inflammatory properties. The first 
steps consisted of the functionalisation of PAMAM dendrimer NPs with 
CS and, later on, with anti-TNF α Abs. Then, it was followed by the 
physicochemical characterisation and further evaluation of their bio-
logical effect. 
Firstly, the successful functionalisation of the PAMAM with CS was 
confirmed through chemical analysis. Fig. 1 shows EDS analysis, 1H 
NMR and FTIR spectra of the CS/PAMAM dendrimer NPs. 
The EDS analysis showed the presence of C, O, and Na atoms at a 
percentage of 58.3%, 34.5% and 0.3%, respectively (Fig. 1a). The 
analysis of functionalised PAMAM also detected a sulphur group (6.9%) 
that does not exist on the PAMAM structure but is a characteristic 
chemical element of chondroitin sulphate, suggesting the PAMAM 
dendrimer’s modification with CS was accomplished [21,22]. 
The PAMAM dendrimer is a branched polymer with an abundance of 
Fig. 3. Rheological rotational (a) and oscillatory (b) assays performed at concentrations 0.1 mg mL− 1 (i) and 0.5 mg mL− 1 (ii) of CS/PAMAM dendrimers.  
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protons, making the identification of full structure on the 1H NMR and 
FTIR spectrum a challenge. Nevertheless, some characteristic chemical 
shifts can be identified, such as the well-defined signals visible on the 1H 
NMR spectra (Fig. 1b). Typical shifts of PAMAM dendrimer were 
observed at 2.4, 2.6, 2.7, 2.8 and 3.5 ppm [23,24] but also chemical 
shifts of chondroitin sulphate (CS-A sodium salt from bovine trachea) 
were found. The signal at 2.04 ppm corresponds to the CH3 and at 4.75 
ppm to the 1H signal of the 4-sulfated site of the galactosamine unit of 
chondroitin sulphate, following the literature [25,26]. Therefore, in the 
functionalised NPs it was observed the presence of characteristics peaks 
from both the PAMAM and CS, indicating the modification was suc-
cessful. Some EDC residues were also observed specifically the chemical 
shifts of 1.1 ppm and 1.9 ppm. The modification was further confirmed 
by the FTIR analysis of the chondroitin sulphate, PAMAM dendrimer, 
and CS/PAMAM dendrimer NPs (Fig. 1c). In the spectra of CS/PAMAM 
dendrimer NPs it was visible the strong and broad peak of absorption at 
around 3400 cm− 1, assigned to the stretching vibration of the structural 
N–H overlapping the O–H stretching [27]. Other characteristic ab-
sorption bands are noticeable, for instance: 1650 cm− 1 for amide bands, 
1240 cm− 1 for S–O stretching vibration, 1415 cm− 1 and 1379 cm-1 for 
the coupling of the C–O stretching vibration and O–H variable-angle 
vibration of –COOH, as described in the literature [28]. The absorp-
tion band assigned to the α-(1,4) glycoside bond was observed at 925 
cm− 1 [27]. Regarding the PAMAM G1.5 spectra, it was also detectable 
the leading characteristic bands such as a characteristic –C = O 
stretching vibrations around 1645 cm− 1 due to the presence of a free 
ester (C = O) group. At the end, expected on half the generation material 
[29], and a peak at 1560 cm− 1 assigned to an O–H or N–H stretching 
vibration. Moreover, peaks at 2970 cm− 1 and 2840 cm− 1 assigned to 
–CH3 and –CH2– stretching vibrations as well as the broad peak around 
3430 cm− 1 attributed to an O–H stretching vibration were also 
observed [27,30]. The CS/PAMAM dendrimer NPs spectrum showed a 
very similar spectrum to the CS, which is expected from a successful 
modification, due to the surface coverage allowed by such a large 
molecule. However, CS is a large molecule able to cover the PAMAM 
surface, being possible that it hides some of the PAMAM characteristic 
peaks. 
7.1.2. Morphology, size and zeta potential of CS/PAMAM NPs 
The morphology of the CS/PAMAM dendrimer NPs was evaluated in 
dry conditions, using AFM and STEM techniques, and in wet conditions 
by DLS and ELS, Fig. 2. 
The characterisation clearly showed that CS/PAMAM dendrimer NPs 
had a globular shape, were monodisperse and presented a polymer 
coating around PAMAM dendrimer NPs, which is in accordance with the 
data found in literature, with/using modified PAMAM dendrimer NPs 
[24,31]. 
DLS and ELS were also used to analyse the CS/PAMAM dendrimer 
NPs. The data obtained by DLS (Fig. 2c) showed the presence of two 
peaks, one small peak with an intensity of approximately 48 nm corre-
sponding to the modified dendrimer (i) and a second peak with an in-
tensity of approximately 300 nm that corresponds to aggregated NPs (ii). 
The aggregation NPs can be caused by the interactions between non-
covalent free sulphur groups/carboxyl groups of Chondroitin sulphate 
and/or not functionalised PAMAM dendrimer NPs (carboxyl-terminal 
dendrimer) and amino groups of Chondroitin sulphate [32]. Moreover, 
zeta potential data indicated that CS/PAMAM dendrimer NPs in PBS, at 
neutral pH, presented negative charge of approximately − 15 mV. The 
data showed that the negatively charged sulphur groups in CS/PAMAM 
dendrimer NPS were mostly distributed at the surface of the nano-
particles, as observed in other studies [33], which once again reveals the 
effectiveness of the functionalisation of PAMAM dendrimer NPs with CS. 
7.1.3. Rheological properties of CS/PAMAM dendrimer NPs 
Drug delivery requires minimally invasive deployment strategies, 
therefore, the biomaterial used needs to have a suitable flow rate (even 
at the maximum pressure applicable), and be easily injected without 
being affected or deformed [34]. The rheological examination was 
performed using the rotational and oscillatory modes, resulting in flow 
behaviour and mechanical analysis of the produced NPs. Flow behaviour 
is described by the fitting of the experimental data with the power-law 
model: τ = k∙γn, where τ is the shear stress (Pa), γ is the shear rate 
(s− 1), k is the consistency coefficient (Pa.sn) and n is the flow behaviour 
index, being n = 1 for Newtonian liquid, n < 1 for shear-thinning fluid 
(non-Newtonian) and n > 1 for swelling plastic fluid [35]. Fig. 3 shows 
the rheological analysis of the CS/PAMAM at 0.1 mg mL− 1 and 0.5 mg 
mL− 1, from rotational and oscillatory experiments. 
The shear-thinning behaviour of both solutions was clearly shown by 
the plot of the viscosity in the function of shear rate curves. Moreover, 
from the flow curves it was obtained the flow behaviour index for each 
solution, which is approximately 0.70 and 0.92 for 0.1 mg mL− 1 and 0.5 
mg mL− 1 CS/PAMAM solutions, respectively. These values categorise 
the samples as shear-thinning fluid, having the highest concentration a 
more stable behaviour when higher stress was applied. Usually, shear- 
thinning fluids are characterised by high viscosity in static conditions 
and in dynamic conditions with a viscosity close to water (n = 1), thus 
decreasing the pressure during injection and facilitating their adminis-
tration [36]. The obtained results are in accordance with the previous 
experiments because CS/PAMAM dendrimer NPs have a viscosity close 
to the water, mainly at the highest concentration (0.5 mg mL− 1). Thus, 
nanoparticles have a good flow behaviour to be injected. 
7.1.4. Anti-TNF-α binding determination 
The CS/PAMAM dendrimer NPs were conjugated to a polyclonal 
Fig. 4. a) Fluorescence spectroscopy of CS/PAMAM dendrimer NPs and anti- 
TNF α Abs-CS/PAMAM dendrimer NPs. b) Percentage of TNF α captured by 
anti-TNF α Abs-CS/PAMAM dendrimer NPs. 
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rabbit anti-TNF-α Abs, and to evaluate their effectiveness, fluorescence 
spectroscopy was performed using CS/PAMAM dendrimer NPs with and 
without linked Abs, in the presence of secondary antibodies labelled 
with Alexa Fluor 488 dye, Fig. 4. 
The emission spectra of Alexa 488 (between 500 and 600 nm) for the 
CS/PAMAM dendrimer NPs without anti-TNF α Abs showed a low 
fluorescence intensity (≃400), indicative of some unspecific secondary 
Abs binding. However, the fluorescence of the anti-TNF α Ab-CS/ 
PAMAM dendrimer NPs was significantly higher (≃1100), thus sug-
gesting the conjugation with the anti-TNF α Abs was accomplished. 
The anti-TNF α Abs-CS/PAMAM dendrimer NP’s capacity to capture 
TNF α was evaluated by the difference between the initial and the final 
amount of free TNF α in solution, after adding the dendrimer NPs. The 
results demonstrated that after 6 h of reaction, between TNF α and anti- 
TNF α Abs-CS/PAMAM dendrimer NPs, the degree of capture was 
65.27%, Fig. 4b. By maintaining this capture rate, the maximum can be 
reached in less than 24 h. The size of the CS/PAMAM dendrimers NPs 
after antibody binding was 58 ± 2.3 nm and the zeta potential − 8.3 mV 
± 5.7, indicating the NPs increased in size and became less negative after 
binding with antibody. Literature reports that positively charged parti-
cles are typically internalised by cells more extensively than negatively 
charged nanoparticles [37,38]. On the other hand, positive nano-
particles are more toxic [39]. For that reason, the negatively charged 
surface of the NPs would favour the cytocompatibility, and in turn, the 
NPs could be specifically internalised or bound to TNF α expressing cells, 
avoiding unspecific cell entry. 
7.2. In vitro studies 
The cell viability and proliferation upon CS/PAMAM dendrimer NPs 
administration and their internalisation, haemolytic properties, inter-
ference with plasma proteins, and therapeutic efficacy was assessed 
using the chondrogenic ATDC 5 cell line, PMA macrophage- 
differentiated THP-1 and T lymphocytic (Jurkat) cell lines, as models 
of target cells. 
7.2.1. Influence of CS/PAMAM dendrimer NPs of ATDC 5, THP1 and 
Jurkat on cell viability and proliferation 
The influence of CS/PAMAM dendrimer NPs on cell viability and 
proliferation was evaluated by MTS and DNA quantification assays 
(Fig. 5(a) (i) and (ii), respectively), using three different concentrations 
of NPs (0.01, 0.1 and 0.5 mg mL− 1) on the ATDC5 cell line for 3 days. 
The MTS and DNA quantification results demonstrated that although 
there were some significant differences between the tested NPs con-
centrations, the cell viability and proliferation increased over time in a 
similar trend than control cells. The cytotoxicity of PAMAM dendrimer 
depends actively on their generation and nature of functional surface 
groups, where high generations and cationic terminal groups often 
exhibit high toxicity, whereas anionic and neutral dendrimers show 
small or no toxic effects. Furthermore, modification of the dendrimer’s 
surface with negatively charged or neutral moieties decreases its cyto-
toxicity [40]. The obtained results are in the accordance with data re-
ported in the literature, as the produced negatively charged CS/PAMAM 
Fig. 5. MTS assay (a, i) and DNA quantification (a, ii) of the ATDC 5 cells. THP1 cells (b, i) and Jurkat cells’ (b, ii) MTS assay. In image a) the cells were incubated 
with media (CTRL) and different CS/PAMAM dendrimer NPs concentrations C1, C2 and C3 (0.01, 0.1 and 0.5 mg mL− 1) at different time points (24, 48 and 72 h). In 
b) the cells were incubated with the CS/PAMAM dendrimer NPs at 0.5 mg mL− 1 for 48 h. Significant differences * p < 0.001 and *p < 0.05, by non-parametric 
Kruskal-Wallis test (a,i), (a,ii) and (b,ii); Ordinary one-way ANOVA (b,i). THP1 and Jurkat cells have not significant differences. 
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dendrimer NPs demonstrated no harmful effects on both cell viability 
and proliferation in the ATDC 5 cell line. 
Besides evaluating the metabolic activity and cell proliferation of 
NPs in ATDC 5 cells, it is vital to study their effect on the immune sys-
tem. When immune cells are exposed to the stimulation they can acti-
vate several signalling pathways that promote different responses, such 
as proliferation, differentiation, migration, and inflammatory and im-
mune response [41]. Macrophages are relevant cells of the innate im-
mune system, implicated in the recognition of foreign pathogens, such as 
nanoparticles, via interaction of their surface structures with different 
types of Pattern Recognition Receptors (PRRs). These cells are also 
responsible for the production of pro-inflammatory and anti- 
inflammatory cytokines and pathogen clearance by phagocytosis [42]. 
In fact, TNF-α is released by immune cells such as macrophages or 
lymphocytes [43]. Having this in mind, the effect of CS/PAMAM den-
drimer NPs on THP-1 and Jurkat cell line was assessed (Fig. 5b). The 
results obtained in the MTS assay indicated that CS/PAMAM dendrimer 
NPs were cytocompatible at all the tested concentrations, in both cell 
lines. Moreover, there were no significant differences in the cells’ 
metabolic activity after dendrimer administration, when compared with 
the control cells. 
7.2.2. Internalisation of the CS/PAMAM NPs by ATDC 5 and THP-1 cell 
lines 
The quantitative and qualitative analysis of the internalisation of 
FITC-labelled dendrimer NPs by cells was performed by flow cytometry 
assay and fluorescence microscopy, using ATDC 5 and THP-1 cell lines, 
Fig. 6. 
ATDC 5 cells were cultured with different concentrations of fluo-
rescently labelled dendrimer NPs and flow cytometry analysis showed 
that all concentrations obtained a high percentage of internalisation at 
72 h (Fig. 6(a) (i)). NPs at 0.5 mg mL− 1 reached the highest and constant 
rate of internalisation over time (Table 1). 
Qualitative images obtained with a fluorescence microscope showed 
typical morphology of the cells (marked by DAPI and phalloidin), sug-
gesting survival and healthy proliferation in all the tested concentrations 
(Fig. 6(a) (ii)). The results showed that C3 (0.5 mg mL− 1) obtained 
almost the maximum internalisation rate at 24 h. For that reason, 
henceforth the experiments were performed with only the concentration 
Fig. 6. Flow cytometry histograms (a) (i) and Fluorescence microscopy images (a) (ii) of the ATDC 5 cell line cultured in presence of different concentrations (C1 
(0.01 mg mL− 1), C2 (0.1 mg mL− 1) and C3 (0.5 mg mL− 1)) of FITC labelled CS/PAMAM dendrimer NPs for 72 h. Flow cytometry (b) (i) and Fluorescence microscopy 
(b) (ii) of differentiated THP-1 cells with CS/PAMAM dendrimer NPs incubation at different time points (3 and 6 h). Cell nuclei are stained in blue (Hoechst) and CS/ 
PAMAM dendrimer NPs in green (FITC). Scale bar: 100 μm (b). (For interpretation of the references to colour in this figure legend, the reader is referred to the web 
version of this article.) 
Table 1 
Percentage of internalisation of FITC labelled CS/PAMAM dendrimer NPs by 
ATDC5 cells at different concentrations of dendrimer and time points.  
Internalisation (%) 
Conditions/time (H) 24 h 48 h 72 h 
C1: 0.01 mg/mL  45.98%  56.08%  74.19% 
C2: 0.1 mg/mL  66.90%  91%  95.32% 
C3: 0.5 mg/mL  98.99%  99.36%  99.88%  
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of 0.5 mg mL− 1 of CS/PAMAM dendrimer NPs. 
The macrophage-differentiated THP-1 cell line was also analysed as 
they are phagocytic cells and can internalise dendrimers on a large scale. 
The FITC-labelled CS/PAMAM dendrimer NPs at 0.5 mg mL− 1 were 
incubated with THP-1 cells at different time points. The flow cytometry 
analysis showed that the internalisation rate was high after 3 h of in-
cubation, in comparison with the control, and increased throughout the 
incubation time (Fig. 6(b) (i)). The internalisation of the CS/PAMAM 
dendrimer NPs by the macrophage cells was further confirmed by 
fluorescence microscopy, as depicted in Fig. 6(b) (ii). 
Fluorescence microscopy confirmed the internalisation of the CS/ 
PAMAM dendrimer NPs, detected also by flow cytometry. The micro-
scopy images showed that after 3 h and 6 h of incubation the cells 
internalised the dendrimers in a high rate and that the CS/PAMAM 
dendrimer NPs were present in both the nucleus and cytoplasm of the 
cells. Despite the high internalisation rate of the dendrimers in ATDC 5 
and macrophage-differentiated THP-1 cells, there was not a reduction on 
the cell viability, as seen in Fig. 5. Hence, the use of the CS/PAMAM 
dendrimer NPs for the targeted delivery of anti-TNF α Abs antibody 
could be a promising strategy to reduce the inflammation, based on the 
high internalisation rate and the absence of negative effects on the 
macrophage viability. Moreover, CS/PAMAM dendrimer NPs could be 
used to explore other therapies targeting inflammatory macrophages. 
7.3. Haemolytic properties and interaction of the CS/PAMAM dendrimer 
NPs with plasma proteins 
Nanoparticles for medical applications must be subjected to 
biocompatibility assessments before their approval for administration in 
patients. The in vitro evaluation of the hemocompatibility is an essential 
part of preclinical development for NPs that will be injected through the 
intravenous route, or any other route in which they can be in contact 
with blood [44]. According to the American Society for Testing and 
Materials (ASTM), medical devices that have direct or indirect blood 
contact must not be haemolytic [45]. Following the ASTM guidelines, a 
biomaterial that induces the lysis of about 0% to 2% of the red blood 
cells is not considered haemolytic. When the burst of blood cells is about 
2% to 5%, the material is partially haemolytic. For values superior to 
5%, it indicates an apparent haemolytic effect [46]. 
The physicochemical properties of nanoparticles can also drastically 
influence plasm protein’s functions and might originate adverse effects, 
such as conformational changes, which can affect their stability and loss 
of protein functionality, alter the interaction with other elements or 
induce an inflammatory or autoimmune response [47,48]. 
Human plasma is constituted of many proteins such as albumin 
(HSA) and fibrinogen, two of the most representative plasma proteins 
that are attached to the surface of several nanoparticles after entering 
the blood circulation [49]. For this reason, it is essential to analyses the 
effect of the dendrimers on those proteins, to ensure there will be no 
deleterious or unexpected effects upon interaction. 
The haemolysis properties and interaction of the CS/PAMAM den-
drimer NPs with plasma proteins are represented in Fig. 7(a) and (b), 
respectively. 
The analysis of the CS/PAMAM dendrimer NPs showed the absence 
of haemolysis at any of the concentrations tested (Fig. 7(a)). The 
absorbance in the supernatant of the samples was similar to the absor-
bance of the negative control (only PBS). Hence, the CS/PAMAM den-
drimer NPs are biocompatible with red blood cells. 
Then it was evaluated the NPs interactions with plasma protein 
(Fig. 7(b) and (c)). 
The comparison of the protein spectra, after incubation with the NPs, 
with the spectra of the proteins alone showed the absence of relevant 
spectral shifts, even at the highest concentration tested, namely 20 μL of 
the sample. Only a minor change was observed for HSA, probably 
associated with an interaction between the NPs and the protein. Hence, 
the NPs are safe regarding protein structure, although alterations in 
other plasma proteins cannot be ruled out from this experiment. How-
ever, the lack of cytotoxicity, haemolytic effect, or major protein 
structural changes showed the excellent hemocompatibility of the NPs 
and their suitability for an in vivo administration. 
7.4. Assessment of metabolic activity, cell proliferation and TNF α 
capture by anti-TNF α Abs-CS/PAMAM dendrimer NPs in THP-1 cell line 
The influence of anti-TNF α Abs conjugation to PAMAM dendrimer 
NPs on metabolic activity and cell proliferation was evaluated using the 
THP-1 cell line. The previous experiments were performed with CS/ 
PAMAM dendrimer NPs without anti-TNF α and the results did not show 
significant toxicity, in the different concentrations tested. In this assay, 
the THP-1 cells were incubated for 7 days with the anti-TNF α Abs-CS/ 
Fig. 7. Percentage of Haemolysis induced by the CS/PAMAM dendrimer NPs at 
different dilutions in contact with blood cells (a) and tryptophan emission 
spectra of an HSA (b) and fibrinogen (c) protein suspension in PBS, before and 
after incubation with CS/PAMAM dendrimer NPs at 20 μg mL− 1. 
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PAMAM dendrimer NPs (0.5 mg mL− 1), to assess the effect of this 
conjugation on cells’ viability and proliferation. 
The anti-TNF α Abs-CS/PAMAM dendrimer NPs’ capacity to decrease 
the levels of TNF α present in the medium was evaluated using differ-
entiated THP-1 cells, which were stimulated with LPS to induce an in-
flammatory scenario. Upon establishment of the inflammation, 4 
conditions were tested: 1) cells without treatment, 2) cells with anti-TNF 
α Abs-CS/PAMAM dendrimer NPs, 3) cells with CS/PAMAM dendrimer 
NPs without Abs and 4) cells with anti-TNF α Abs alone. Cells differ-
entiated with PMA but without LPS stimulation were used as control. 
Fig. 8 shows the metabolic activity and cell proliferation of THP-1 cells 
upon NPs administration and the quantity of free TNF α (uncaptured) 
over time of incubation with the NPs. 
The cells’ metabolic activity (Fig. 8a) and cell proliferation (Fig. 8b) 
were not affected by the presence of anti-TNF α Abs-CS/PAMAM den-
drimer NPs when compared to control cells. 
The TNF α capture by anti-TNF α Abs-CS/PAMAM dendrimer NPs 
and the capacity of the CS-modified dendrimer NPs to inhibit the release 
of TNF α were also evaluated. The results obtained showed that un-
treated LPS-stimulated cells presented high levels of free TNF α in the 
medium, compared to the remaining conditions, as expected. The levels 
of TNF α dropped significantly in the cells treated with anti-TNF α Abs 
CS/PAMAM dendrimer NPs, being even lower than the CS/PAMAM 
dendrimer NPs or the anti-TNF α Abs alone. Moreover, this trend was 
maintained throughout the time tested, as the TNF α levels continued 
decreasing up to 7 days (Fig. 8c). 
The CS/PAMAM dendrimer NPs without anti-TNF α Abs also showed 
the ability to reduce TNF α levels significantly. These results are 
consistent with the literature that indicates that CS administration has 
an inhibitory effect on the release of TNF-α release, due to the anti- 
inflammatory activity of this sulphated glycosaminoglycan [50–52]. 
The combination of both effects, namely the anti-inflammatory effect of 
the CS and the presence of the anti-TNF α Abs, has probably increased 
the therapeutic efficacy of anti-TNF α Abs-CS/PAMAM dendrimer NPs 
by reducing the production and enhancing the capture of the pro- 
inflammatory cytokine. Although no statistically significant differ-
ences were observed, a trend was visible as the free TNF α decreases over 
time, with a more pronounced effect on the dendrimers with Abs, 
indicating a combined effect of the CS with the Abs. 
Rheumatoid arthritis is characterised by an imbalance between a 
pro-inflammatory and anti-inflammatory cytokines, that is, upregula-
tion of pro-inflammatory cytokines and downregulation of anti- 
inflammatory cytokines [53,54]. Since the pro-inflammatory pheno-
type is more evident in the synovial joints of patients with RA [55] only 
the pro-inflammatory cytokines were evaluated and more specifically 
TNF-α. 
In fact, the model used in this study is a model of inflammation 
however, the inflammatory environment is a usual condition in rheu-
matoid arthritis. Through this model, it is possible to verify the anti- 
inflammatory effect of the anti-TNF α Abs-CS/PAMAM dendrimer NPs 
that can potentially be used in the treatment of several inflammatory 
pathologies including rheumatoid arthritis. 
8. Conclusion 
In this work, an innovative therapeutic approach comprising anti- 
TNF α Abs-CS/PAMAM dendrimer NPs was developed, to provide a 
more targeted and effective anti-inflammatory effect for the manage-
ment of several inflammatory including RA disease. The main goal of 
this approach was to develop a therapeutic and efficient strategy, 
Fig. 8. Metabolic activity (a), Cell proliferation (b) and amount of uncaptured TNF α (c) under different conditions: cells differentiated with PMA but without LPS 
stimulation (C); cells stimulated with LPS,without treatment (1), anti-TNF α Abs-CS/PAMAM (2), CS/PAMAM, without Abs conjugated (3) and anti-TNF α Abs, (4) 
and. Significant differences *** p < 0.001 and *p < 0.05. Mann-Whitney test (a), Unpaired t-test (b) nonparametric Kruskal-Wallis test (c). 
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through the maximum capture of TNF α by anti-TNF α Abs-CS/PAMAM 
dendrimer NPs and the synergistic inhibition of the inflammation by the 
CS. The proposed formulation showed appropriate mechanical and 
rheological properties and exhibited higher TNF α capture capacity than 
the anti-TNF α Abs alone, showing that this system could be useful for 
controlled and sustained drug delivery. The in vitro studies demonstrated 
that CS/PAMAM dendrimer NPs presence did not produce a deleterious 
effect on the tested cells’ metabolic activity and proliferation, thus 
presenting a suitable cytocompatibility and hemocompatibility. The 
anti-TNF α Abs-CS/PAMAM dendrimer NPs properties owe them the 
potential to complement or improve current strategies in the treatment 
of rheumatoid arthritis. 
9. Future perspective 
Recent studies using dendrimers show their great specificity in the 
delivery of the drugs to the site of interest. Having this in mind, it was 
hypothesised that PAMAM dendrimer functionalised with CS and linked 
to specific antibodies (anti-TNF α) could help in the treatment of RA. The 
combinatory approach presented here showed a synergistic effect of 
capture ability of the target agent over time and reduction of this pro-
duction, showing great potential to be used as a specific and sustained 
treatment in RA patients. Despite the encouraging results showed in this 
work, further studies are required to clarify the underlying mechanisms. 
Therefore, future work will comprise the proof of concept of this system 
in vivo, through an animal model of RA. In the future, dendrimers will 
undoubtedly have an important role in the world of nano-
pharmaceuticals, and in particular, in patient-specific approaches for RA 
treatment. 
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Bioelectron. 74 (2015) 376–383. 
[49] B.-J.L. Van Hong Nguyen, International Journal of Nanomedicine, 12 (2017) 3137. 
[50] F. Ronca, L. Palmieri, P. Panicucci, G. Ronca, Osteoarthr. Cartil. 6 (1998) 14–21. 
I.M. Oliveira et al.                                                                                                                                                                                                                              
Materials Science & Engineering C 121 (2021) 111845
13
[51] S.E. Tully, M. Rawat, L.C. Hsieh-Wilson, J. Am. Chem. Soc. 128 (2006) 7740–7741. 
[52] G.M. Campo, A. Avenoso, S. Campo, A.M. Ferlazzo, D. Altavilla, A. Calatroni, 
Arthritis Res Ther 5 (2003) R122. 
[53] S. Mateen, A. Zafar, S. Moin, A.Q. Khan, S. Zubair, Clinica Chimica Acta; 
International Journal of Clinical Chemistry, 455 (2016) 161–171. 
[54] B. Soler Palacios, L. Estrada-Capetillo, E. Izquierdo, G. Criado, C. Nieto, C. Municio, 
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